Pharming Group NV News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.10.24	Pharming Group reports third quarter 2024 financial results and provides business update (GlobeNewswire)
10.10.24	Pharming Group to report third quarter 2024 financial results on October 24 (GlobeNewswire)
10.10.24	Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation (GlobeNewswire)
26.09.24	Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) (GlobeNewswire)
18.07.24	Pharming Group to report second quarter and first half 2024 financial results on August 1 (GlobeNewswire)
03.06.24	Pharming Group to participate in June investor conferences (GlobeNewswire)
30.05.24	Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union (GlobeNewswire)
21.05.24	Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
20.05.24	Pharming Group to participate in May investor conference (GlobeNewswire)
15.05.24	Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 (GlobeNewswire)
08.05.24	Pharming Group reports first quarter 2024 financial results and provides business update (GlobeNewswire)
24.04.24	Pharming Group to report first quarter 2024 financial results on May 8 (GlobeNewswire)
24.04.24	Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards (GlobeNewswire)
19.04.24	Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 (GlobeNewswire)
18.04.24	Pharming Group announces the placement of €100 million convertible bonds due 2029 (GlobeNewswire)
18.04.24	Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 (GlobeNewswire)
08.04.24	Pharming announces completion of enrollment in pediatric clinical trial of leniolisib (GlobeNewswire)
04.04.24	Pharming Group announces the 2024 Annual General Meeting of Shareholders (GlobeNewswire)
04.04.24	Pharming Group announces the filing of its 2023 Annual Report and Form 20-F (GlobeNewswire)
03.04.24	Pharming Group to participate in April investor conferences (GlobeNewswire)
14.03.24	Pharming Group reports fourth quarter and full year 2023 financial results (GlobeNewswire)
29.02.24	Pharming Group to report fourth quarter and full year 2023 financial results on March 14 (GlobeNewswire)
08.02.24	Pharming Group to participate in February investor conferences (GlobeNewswire)
08.01.24	Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update (GlobeNewswire)
13.12.23	Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs) (GlobeNewswire)
21.11.23	Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib (GlobeNewswire)
10.11.23	Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval (GlobeNewswire)
26.10.23	Pharming Group reports third quarter 2023 financial results (GlobeNewswire)
12.10.23	Pharming Group to report third quarter 2023 financial results on October 26 (GlobeNewswire)
25.09.23	Pharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders (GlobeNewswire)
21.02.23	Pharming announces first patient enrolled in pediatric clinical trial of leniolisib (PR Newswire)
28.10.22	Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib (PR Newswire)
04.06.21	Pharming Group N.V. announces the reimbursement of RUCONEST® in Spain (PR Newswire)
01.06.21	Pharming Group to present at Jefferies Virtual Healthcare Conference (PR Newswire)
19.05.21	Pharming Reports on Annual General Meeting of Shareholders (PR Newswire)
17.05.21	Pharming celebrates the 10th annual "hae day :-)" (PR Newswire)
13.05.21	Pharming Group reports financial results for the first quarter of 2021 (PR Newswire)
22.04.21	Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction (PR Newswire)
07.04.21	Pharming Group announces the filing of its 2020 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (PR Newswire)
06.04.21	Pharming Group announces the publication of its 2020 Annual Report and convenes its 2021 AGM (PR Newswire)
23.03.21	Pharming Group announces the intention to nominate three Non-Executive Directors to the Board of Directors (PR Newswire)
16.03.21	Pharming Group to present at 31st Annual Oppenheimer Healthcare Conference (PR Newswire)
11.03.21	Pharming Group to Present at BioCapital Europe 2021 (PR Newswire)
04.03.21	Pharming Group reports financial results for full year 2020 (PR Newswire)
02.03.21	Pharming Group, in collaboration with Invitae Corporation, launches genetic testing program 'navigateAPDS' in US and Canada (PR Newswire)
23.12.20	Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs (PR Newswire)
23.12.20	Pharming Group announces ADSs admitted to trade on Nasdaq under the symbol "PHAR" (PR Newswire)
11.12.20	Pharming Reports on Extraordinary General Meeting of Shareholders (PR Newswire)
10.12.20	Pharming announces enrolment of first patient in US clinical trial for the treatment of COVID-19 with RUCONEST® (PR Newswire)
26.11.20	Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ordinary Shares on Nasdaq Global Market (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Pharming Group NV

Aktien Top/Flop

Meistgelesene Nachrichten